Xilio Therapeutics, Inc. (XLO)
NCM · Healthcare · Biotechnology
$9.10
-0.55%
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
Market Cap
$59.8M
Shares Outstanding
6.6M
P/S (TTM)
1.1x
Exchange
NCM
Currency
USD
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 8.1M | 19.1M | 13.7M | 12.6M |
| Operating Income | -14.4M | -1.9M | -11.8M | -14.1M |
| Net Income | -15.8M | -16.3M | 10.4M | -9.5M |
| Diluted EPS | $-2.24 | $-1.54 | $0.81 | $-0.58 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 6.3M | 43.8M |
| Operating Income | -89.1M | -79.1M | -59.6M | -42.0M |
| Net Income | -88.2M | -76.4M | -58.2M | -35.0M |
| Diluted EPS | $-45.08 | $-38.92 | $-15.26 | $-4.19 |